2022
In November 2022, Boule received IVDR certification for Swelab Alfa Plus and Medonic M32 hematology instruments.
Boule Academy™, a strategic initiative to share and develop knowledge for employees, partners and end users, is launched in 2022.
2021
We revised our strategy to focus even more on our customers and distributors, accelerated our efforts to bring our latest proprietary technology platform and related cloud solutions to fruition. We opened a factory in Russia, a couple of sales offices in Africa and the Middle East and our latest, fully automated, blood controls manufacturing system came online at our facility in the US.
2020
COVID-19 pandemic hit the world and caused significant shifts in demand and buying patterns, impacting customers, end-users and ourselves. Despite all challenges, Boule stayed close to its customers and maintained a strong focus on key development programs.
2018
Boule’s product portfolio is expanded with Swelab and Medonic 5-part hematology instruments, a new Exigo veterinary hematology platform, a new Exigo veterinary chemistry system. Subsidiary in Russia is established.
2017
As a part of the process to bring Boule to the next level, the company reformulates its mission, vision and business concept, and new strategies, targets and core values are implemented.
2015
Boule relocates the Swedish operations to Spånga in north of Stockholm.
2014
A new instrument generation, Swelab Alfa Plus and Medonic M-series M32, are introduced.
2013
A subsidiary in Mexico and sales office in India are established.
2011
Boule is listed on Nasdaq Stockholm.
2010
The Quintus 5-part hematology system is launched.
2009
The Medonic M-series systems receive 510(k) clearance in the USA.
2007
CDS obtains ISO certification, entailing that all companies in the Group now hold ISO 13485 certification.
2006
The company launches a new instrument generation based on a shared platform for Medonic, Swelab and Exigo instruments.
2004
Boule’s hematology system, Medonic CA 620, receives 510(k) clearance in the USA. Boule acquires its partner CDS. The first veterinary hematology system Medonic CA Vet was launched.
2003
Boule establishes reagent manufacturing for blood cell counting in Sweden.
2002
Boule Diagnostics AB and Clinical Diagnostic Solutions, Inc. began their collaboration in 2002. CDS develops, produces and markets reagents and blood controls for clinical diagnostics in hematology.
2001
Boule conducts a private placement to fund the development of the new core business, hematology systems for human and veterinary markets.
1999
Clinical Diagnostic Solutions introduced CDS Brands.
1998
Boule acquires the instrument manufacturer Medonic AB, founded in the 1980s. Boule becomes ISO certified.
1997
Boule acquires the instrument manufacturer Swelab Instrument AB. Clinical Diagnostic Solutions, Inc. was founded in 1997.
1996
Boule Diagnostics AB (’Boule’) is formed as parent company for the Group.
1992
Karo Bio Diagnostics AB is acquired by the present principal owner of Boule Diagnostics AB. Karo Bio Diagnostics AB is a pharmaceutical company focused on the research and development of innovative drugs for unmet medical needs.
1982
Medonic AB is founded by Ingemar Berndtsson and Bram Bottema.
1969
Swelab Instrument AB is founded by Erik Öhlin.
1956
The first European cell counter is developed by Erik Öhlin.
